BEAVERTON, Ore., Oct. 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- DataVault AI, Inc. ("DataVault") (NASDAQ:DVLT), leading the way in AI data experience, valuation, and monetization, and Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the two companies have entered into a non-binding letter of intent to implement manufacturer-to-patient blockchain-enabled smart contracts ("PharmacyChain™") into Wellgistics proprietary Technology and Physical infrastructure for the prescription drug industry. The goal of the partnership will be to seek to fully digitize t

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX), a growing force in pharmaceutical distribution and healthcare technology, will appear live on YouTube via the Floorstocks channel (@floorstocks) this Tuesday, July 22 at 1:00 PM EST. CEO Brian Norton will participate in an unfiltered discussion covering WGRX's recent momentum, stock performance, market outlook, and the company's strategy ahead. Floorstocks—the platform known for amplifying rising public companies—will host this live session, providing retail investors direct engagement. Why Tune In? Hear firsthand insight from CEO Brian Norton on the company's latest developmentsDeep dive into WGRX

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Floorstocks, a financial media platform with over 1.2 million active retail investors, has released an exclusive CEO interview filmed at the Nasdaq MarketSite with Brian Norton, CEO of Wellgistics Health Inc. (NASDAQ:WGRX). The full interview is now available on YouTube and Floorstocks.com, offering investors a front-row look at one of healthcare's most disruptive emerging growth companies. Watch the full interview on YouTube:https://youtu.be/gJJlbqd7Mv8 Also streaming at Floorstocks.com:https://www.floorstocks.com Hosted by market veteran Kenneth Polcari, the interview unpacks how Wellgistics is modernizing the $600+ billion U.S. prescription

Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner. This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity

Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner. This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity

Dear Shareholders, TAMPA, FL, March 27, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health"), This time last year, Wellgistics was a private company, weathering the pressures of a broken pharmaceutical supply chain plagued with waste, inefficiencies, and a lack of pricing transparency that has decimated independent pharmacies and other stakeholders in the healthcare ecosystem. Today, we are a public company listed on the Nasdaq exchange under our new parent company name, Wellgistics Health, Inc. (NASDAQ:WGRX), we have completed several acquisitions that broaden our service offerings, and we have a full year 2024 pro forma consolidated net sales (assuming

TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health"), a provider of pharmacy solutions and healthcare technology, has successfully completed a third-party audit and achieved SOC 2 Type 1 compliance. This milestone validates that Wellgistics Health meets the industry's highest standards for security, availability, processing integrity, confidentiality, and privacy, reinforcing its commitment to data protection and regulatory compliance. SOC 2 Type 1 certification, developed by the American Institute of Certified Public Accountants (AICPA), confirms that Wellgistics Health has implemented strong security controls and operational safegua

TAMPA, FL, March 04, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX) (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that Tim Canning, Chief Executive Officer, will be departing the company. Mr. Canning's leadership tenure helped guide Wellgistics Health through pivotal phases, and the Company expresses gratitude for his contributions. Brian Norton has been officially appointed as Chief Executive Officer. Mr. Norton has a proven track record of success and expertise in healthcare, technology, and pharmaceutical supply chain innovation and has led high

ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond™, is designed to provide multiple levels of protection Princeton, New Jersey, March 04, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX, the ", Company", )), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, is collaborating with Protega Pharmaceuticals Inc. ("Protega"). Protega is the innovative specialty pharmaceutical company that launched ROXYBOND™ (oxycodone hydrochloride), the first and only FDA-approved abuse-deterrent imme

Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX, the ", Company", )), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC ("Tollo") to market Tollo's emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, including muscle loss and Long COVID to pharmacies. Tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with GLP-1 drug use, and pe

3 - Wellgistics Health, Inc. (0002030763) (Issuer)

3 - Wellgistics Health, Inc. (0002030763) (Issuer)

4 - Wellgistics Health, Inc. (0002030763) (Issuer)

3 - Wellgistics Health, Inc. (0002030763) (Issuer)

3 - Wellgistics Health, Inc. (0002030763) (Issuer)

3 - Wellgistics Health, Inc. (0002030763) (Issuer)

4 - Wellgistics Health, Inc. (0002030763) (Issuer)

4 - Wellgistics Health, Inc. (0002030763) (Issuer)

4 - Wellgistics Health, Inc. (0002030763) (Issuer)

4 - Wellgistics Health, Inc. (0002030763) (Issuer)

8-K - Wellgistics Health, Inc. (0002030763) (Filer)

PRE 14C - Wellgistics Health, Inc. (0002030763) (Filer)

8-K - Wellgistics Health, Inc. (0002030763) (Filer)

8-K - Wellgistics Health, Inc. (0002030763) (Filer)

8-K - Wellgistics Health, Inc. (0002030763) (Filer)

8-K - Wellgistics Health, Inc. (0002030763) (Filer)

424B4 - Wellgistics Health, Inc. (0002030763) (Filer)

EFFECT - Wellgistics Health, Inc. (0002030763) (Filer)

S-1/A - Wellgistics Health, Inc. (0002030763) (Filer)

S-1/A - Wellgistics Health, Inc. (0002030763) (Filer)

Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner. This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity

Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner. This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity